Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer trials while focusing on immunology leadership ...

The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.

In a report released on April 22, Nicolas Pauillac from Kepler Capital maintained a Hold rating on Sanofi (SNYNF – Research Report). The ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

Investing.com – France equities were lower at the close on Wednesday, as losses in the Healthcare, Oil & Gas and Industrials ...

Credit: Kateryna Kon / Shutterstock. At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with ...

What is the Price to Earnings Growth (PEG) Ratio? The PEG Ratio chart for Sanofi-aventis Ads (SNY) compares PE to EPS Growth rates. Defining fair value is the goal of measuring valuation using the PEG ...